LOUISVILLE, Ky. / Feb 23, 2023 / Business Wire / Humana Inc. (NYSE: HUM) announced today that Bruce D. Broussard, President and Chief Executive Officer, will make a presentation to investors at the Cowen Health Care Conference on Tuesday, March 7, 2023, at 9:10 a.m. Eastern time.
A live audio webcast of the presentation will be available via Humana’s Investor Relations page at humana.com. The company suggests webcast participants sign on approximately 15 minutes in advance of the presentation to allow time to run a system test and download any free software needed for access purposes.
About Humana
Humana Inc. (NYSE: HUM) is committed to helping our millions of medical and specialty members achieve their best health. Our successful history in care delivery and health plan administration is helping us create a new kind of integrated care with the power to improve health and well-being and lower costs. Our efforts are leading to a better quality of life for people with Medicare, families, individuals, military service personnel, and communities at large.
To accomplish that, we support physicians and other health care professionals as they work to deliver the right care in the right place for their patients, our members. Our range of clinical capabilities, resources and tools – such as in-home care, behavioral health, pharmacy services, data analytics and wellness solutions – combine to produce a simplified experience that makes health care easier to navigate and more effective.
More information regarding Humana is available to investors via the Investor Relations page of the company’s web site at humana.com, including copies of:
| Last Trade: | US$260.67 |
| Daily Change: | 0.39 0.15 |
| Daily Volume: | 1,270,775 |
| Market Cap: | US$31.350B |
December 16, 2025 November 05, 2025 October 20, 2025 August 27, 2025 | |

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load